The radiopharmaceutical 68Ga-PSMA-11 represents a radiopharmaceutical drug without marketing authorization for the prostate cancer diagnosis in a specific treatment program. In respect of the radiopharmaceutical technology, the difficultness of the preparation of 68Ga-PSMA-11 is comparable to that of conventional radiopharmaceuticals.

The radiopharmaceutical 68Ga-DOTATOC represents the latest radiopharmaceutical in the diagnosis of a neuroendocrine tumor with somatostatin receptor overexpression. Technological and economic difficulties of preparing and quality control of the radiopharmaceutical limit its use to specialised departments. Background of the department with rich experience with radiopharmaceuticals for positron emission tomography allows handling more difficult 68Ga-radiopharmacy and may increase and improve the care of oncology patients.